These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 11216519)

  • 1. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors.
    Anderson CJ; Dehdashti F; Cutler PD; Schwarz SW; Laforest R; Bass LA; Lewis JS; McCarthy DW
    J Nucl Med; 2001 Feb; 42(2):213-21. PubMed ID: 11216519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiotherapy and dosimetry of 64Cu-TETA-Tyr3-octreotate in a somatostatin receptor-positive, tumor-bearing rat model.
    Lewis JS; Lewis MR; Cutler PD; Srinivasan A; Schmidt MA; Schwarz SW; Morris MM; Miller JP; Anderson CJ
    Clin Cancer Res; 1999 Nov; 5(11):3608-16. PubMed ID: 10589778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients.
    Pfeifer A; Knigge U; Binderup T; Mortensen J; Oturai P; Loft A; Berthelsen AK; Langer SW; Rasmussen P; Elema D; von Benzon E; Højgaard L; Kjaer A
    J Nucl Med; 2015 Jun; 56(6):847-54. PubMed ID: 25952736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo evaluation of copper-64-octreotide conjugates.
    Anderson CJ; Pajeau TS; Edwards WB; Sherman EL; Rogers BE; Welch MJ
    J Nucl Med; 1995 Dec; 36(12):2315-25. PubMed ID: 8523125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study.
    Pfeifer A; Knigge U; Mortensen J; Oturai P; Berthelsen AK; Loft A; Binderup T; Rasmussen P; Elema D; Klausen TL; Holm S; von Benzon E; Højgaard L; Kjaer A
    J Nucl Med; 2012 Aug; 53(8):1207-15. PubMed ID: 22782315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors.
    Janson ET; Westlin JE; Ohrvall U; Oberg K; Lukinius A
    J Nucl Med; 2000 Sep; 41(9):1514-8. PubMed ID: 10994731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastroenteropancreatic tumor imaging with somatostatin receptor scintigraphy.
    Wiedenmann B; Bäder HM; Scherubl H; Fett U; Zimmer T; Hamm B; Koppenhagen K; Riecken EO
    Semin Oncol; 1994 Oct; 21(5 Suppl 13):29-32. PubMed ID: 7992077
    [No Abstract]   [Full Text] [Related]  

  • 8. Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients.
    Virgolini I; Szilvasi I; Kurtaran A; Angelberger P; Raderer M; Havlik E; Vorbeck F; Bischof C; Leimer M; Dorner G; Kletter K; Niederle B; Scheithauer W; Smith-Jones P
    J Nucl Med; 1998 Nov; 39(11):1928-36. PubMed ID: 9829585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiotherapy, toxicity and dosimetry of copper-64-TETA-octreotide in tumor-bearing rats.
    Anderson CJ; Jones LA; Bass LA; Sherman EL; McCarthy DW; Cutler PD; Lanahan MV; Cristel ME; Lewis JS; Schwarz SW
    J Nucl Med; 1998 Nov; 39(11):1944-51. PubMed ID: 9829587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake.
    Kwekkeboom DJ; Kooij PP; Bakker WH; Mäcke HR; Krenning EP
    J Nucl Med; 1999 May; 40(5):762-7. PubMed ID: 10319747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide.
    Bangard M; Béhé M; Guhlke S; Otte R; Bender H; Maecke HR; Biersack HJ
    Eur J Nucl Med; 2000 Jun; 27(6):628-37. PubMed ID: 10901448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subcellular localization of radiolabeled somatostatin analogues: implications for targeted radiotherapy of cancer.
    Wang M; Caruano AL; Lewis MR; Meyer LA; VanderWaal RP; Anderson CJ
    Cancer Res; 2003 Oct; 63(20):6864-9. PubMed ID: 14583484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Scintigraphy of somatostatin receptors in the diagnosis and staging of neuroendocrine tumors of the digestive tract and pancreas].
    Banzo J; Abós MD; Prats E; García F; Razola P
    Rev Esp Med Nucl; 2000 Jun; 19(3):225-41. PubMed ID: 11062088
    [No Abstract]   [Full Text] [Related]  

  • 14. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy.
    Srirajaskanthan R; Kayani I; Quigley AM; Soh J; Caplin ME; Bomanji J
    J Nucl Med; 2010 Jun; 51(6):875-82. PubMed ID: 20484441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide.
    Förster GJ; Engelbach MJ; Brockmann JJ; Reber HJ; Buchholz HG; Mäcke HR; Rösch FR; Herzog HR; Bartenstein PR
    Eur J Nucl Med; 2001 Dec; 28(12):1743-50. PubMed ID: 11734910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 110mIn-DTPA-D-Phe1-octreotide for imaging of neuroendocrine tumors with PET.
    Lubberink M; Tolmachev V; Widström C; Bruskin A; Lundqvist H; Westlin JE
    J Nucl Med; 2002 Oct; 43(10):1391-7. PubMed ID: 12368379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo evaluation of 64Cu-TETA-Tyr3-octreotate. A new somatostatin analog with improved target tissue uptake.
    Lewis JS; Srinivasan A; Schmidt MA; Anderson CJ
    Nucl Med Biol; 1999 Apr; 26(3):267-73. PubMed ID: 10363797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of somatostatin receptor scintigraphy.
    Kwekkeboom DJ; Lamberts SW; Habbema JD; Krenning EP
    J Nucl Med; 1996 Jun; 37(6):886-92. PubMed ID: 8683305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of four 64Cu-labeled somatostatin analogues in vitro and in a tumor-bearing rat model: evaluation of new derivatives for positron emission tomography imaging and targeted radiotherapy.
    Lewis JS; Lewis MR; Srinivasan A; Schmidt MA; Wang J; Anderson CJ
    J Med Chem; 1999 Apr; 42(8):1341-7. PubMed ID: 10212119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.
    Barone R; Walrand S; Konijnenberg M; Valkema R; Kvols LK; Krenning EP; Pauwels S; Jamar F
    Nucl Med Commun; 2008 Mar; 29(3):283-90. PubMed ID: 18349800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.